Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"A Phase IIa Pharmacokinetic-pharmacodynamic Study to Confirm the Inhibitory Effect of Temsirolimus, Targeting the mTOR Pathway in Endometrial Carcinoma"

NCT02093598 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT02093598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02093598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"A Phase IIa Pharmacokinetic-pharmacodynamic Study to Confirm the Inhibitory Effect of Temsirolimus, Targeting the mTOR Pathway in Endometrial Carcinoma"
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
March 31, 2014
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, endometrioid, mtor protein